Morinaga Milk Industry Co., Ltd., (TOKYO:2264) today announced it has attained self-affirmed GRAS (generally recognized as safe) status in the United States for LAC-Shield, a unique immunogenic ingredient. This development opens the door for manufacturers of […]
Jennewein Biotechnologie announces that on June 15, 2018, it signed a long-term lease for a 1000-m2 plot of land on Mildred-Scheel-Straße, Bonn Bad Godesberg, which will be the site of a new R&D centre for […]
Paris (France), July 5, 2018 – Nextbiotix, a microbiome biotech company developing innovative Live Biotherapeutics using commensal bacteria as drugs to treat major inflammatory bowel diseases, today announced that it has completed a €7m Series […]
On April 6, 2018, BioGaia became the majority shareholder in MetaboGen with a 62 percent stake. BioGaia has now, after the set milestones have been achieved, decided to further extend its holding, resulting in a […]
Archer Daniels Midland Company (NYSE: ADM) announced today that it has reached an agreement to acquire Probiotics International Limited (PIL), a U.K.-based provider of probiotic supplements for human, pet, and production-animal use. The all-cash transaction […]
Twenty laboratory mice are poised to play an important role in preparing humans to go to Mars. A Northwestern University-led study of the microbiome in space is one of five science investigations scheduled to launch […]
CEO Mauricio Graber: “We are pleased to report that we maintained the sales momentum in Q3″ Chr. Hansen reports solid organic revenue growth of 9% in the first nine months of 2017/18 (3% reported growth due to […]
Microbiome Times got in touch with Dr Edward Green, CEO of CHAIN Biotechology Ltd – a UK based microbiome Company focused on the development and commercialization of microbial technology for the production and delivery of biotherapeutics. Dr Edward […]
As reported on November 17, 2017 a randomized, double-blind, placebo-controlled study in 90 older women showed that supplementation of the probiotic strain Lactobacillus reuteri ATCC PTA 6475 decreased bone loss compared to placebo. The study […]
Kaleido Biosciences, a clinical-stage healthcare company leading the development of novel chemistries to drive functions of the microbiome organ, today announced that it has closed $101 million in an oversubscribed Series C financing. Several new […]
After 10 years and a worldwide effort, Crohn’s and Colitis Canada is pleased to announce that the world-renowned Genetic, Environmental, Microbial (GEM) Project has reached its goal of 5,000 participants. Launched in 2008 at Mount […]